Press Releases

Press ReleaseChengdu, China, April 10, 2024Anticancer Bioscience unveils groundbreaking MYC-Synthetic Lethal Therapy at AACR 2024 Chengdu, China, April 10, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that their research team at the 2024 AACR Conference introduced a pioneering therapy aimed at cancer with the deregulated …

Anticancer Bioscience unveils groundbreaking MYC-Synthetic Lethal Therapy at AACR 2024 Read More »

Press ReleaseChengdu, China, September 22, 2022Anticancer Bioscience named a finalist for China Biopharma Leadership Award by Scrip Chengdu, China, September 22, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that it has been named as a finalist for the 2022 Scrip Awards in the category of China …

Anticancer Bioscience named a finalist for China Biopharma Leadership Award by Scrip Read More »

Press ReleaseChengdu, China, May 18, 2022Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology Chengdu, China, May 18, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, based in China, and DelSiTech Ltd, the leading silica drug delivery technology company, based in …

Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology Read More »

Press ReleaseChengdu, China, April 19, 2022Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader Chengdu, China, April 19, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that its Founder, President and CEO, Dun Yang, PhD has been named as …

Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader Read More »

Press ReleaseChengdu, China, January 17, 2022Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics Chengdu, China, January 17, 2022 - The Discovery Oncology (DO) group and the Natural Product Drug Discovery (NPDD) group of Anticancer Bioscience (ACB) collaboratively published another interesting study that uncovers a novel mechanism by which a natural …

Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics Read More »

Press ReleaseChengdu, China, January 8, 2022Dr. Allen, VP of Anticancer Bioscience, presented his insights on personalized / precision medicine at a roundtable discussion organized by Pharma's Almanac Chengdu, China, January 8, 2022 - Dr. Thaddeus Allen, VP of Translational Biology and Business Development, was invited for a roundtable discussion by Pharma’s Almanac on January 7th, …

Dr. Allen, VP of Anticancer Bioscience, Presented His Insights on Personalized / Precision Medicine at a Roundtable Discussion Organized by Pharma’s Almanac Read More »

Press ReleaseChengdu, China, December 20, 2021Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China Chengdu, China, December 20, 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that to accommodate its growth and expansion, and on the back of its recent financing, it …

Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China Read More »

PRESS RELEASEChengdu, China, October 25, 2021Anticancer Bioscience Has Been Named as One of the ‘50 Most Admired Companies Of The Year 2021’ By The Silicon Review Chengdu, China, October 25, 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, has been named as one of the ‘50 Most Admired Companies of …

Anticancer Bioscience Has Been Named as One of the ‘50 Most Admired Companies Of The Year 2021’ By The Silicon Review Read More »

PRESS RELEASEChengdu, China, October 14, 2021Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31M to Advance Synthetic Lethality Approaches to Cancer Therapy Chengdu, China, October 14, 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that it had secured an additional CNY 68.4 …

Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31M to Advance Synthetic Lethality Approaches to Cancer Therapy Read More »

PRESS RELEASEChengdu, China, September 9, 2021Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments Chengdu, China, September 9, 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today its first granted US patent (11104633), entitled “cancer treatment using compounds that selectively target polyploid …

Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments Read More »